ALT
- Altimmune, Inc.
()
Overview
Company Summary
Altimmune, Inc. is a biopharmaceutical company that specializes in developing and commercializing immunotherapies for various infectious diseases and other health conditions. The company's primary focus is on the discovery and development of novel vaccines and therapeutics that activate the immune system to prevent or treat diseases.
Altimmune has developed a proprietary vaccine technology platform called RespirVec�, which enables the development of single-dose vaccines that induce both systemic and mucosal immunity. This platform has the potential to offer long-lasting protection against a wide range of infectious diseases, including influenza, COVID-19, and hepatitis B.
The company's pipeline includes several vaccine candidates at various stages of development. Altimmune's most advanced product candidate is NasoVAX, a nasal spray influenza vaccine that has completed Phase 2 clinical trials. NasoVAX is designed to generate an immune response not only in the nasal passages but also in the systemic immune system, potentially providing broader and more robust protection against influenza viruses.
In addition to influenza vaccines, Altimmune is actively working on development programs for other infectious diseases. ALT-801, for example, is an investigational therapy under development for the treatment of chronic hepatitis B infection. The company is also leveraging its expertise in immune modulation to explore potential applications in immuno-oncology, aiming to develop therapies that target and modulate the immune system to fight cancer.
Overall, Altimmune, Inc. focuses on utilizing their innovative vaccine platform to develop immunotherapies that can address unmet medical needs, protect people from infectious diseases, and potentially improve outcomes in various disease areas.